Overview: Merck saw a drop in quarterly sales of Januvia, a diabetes drug that has been under scrutiny by the U.S. Food and Drug Administration (FDA) due to research linking it to pancreatic cancer. Januvia is part of a class of drugs called incretin mimetics. Other medications in this class include: exenatide (Byetta, Bydureon), liraglutide (Victoza), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina, Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto). Januvia and Byetta lawsuits have been consolidated into a multidistrict litigation; plaintiffs allege that the drugs caused pancreatic cancer or pancreatitis.
Product: Januvia (sitagliptin), Byetta (exenatide)
Manufacturer: Merck & Co., Bristol-Myers Squibb Co.
Side Effects & Complications
- Pancreatic cancer
- Thyroid cancer